Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer

Genetic and epigenetic changes in the mitogen activated protein kinase (MAPK) signaling render urothelial cancer a potential target for tyrosine kinase inhibitor (TKI) treatment. However, clinical trials of several TKIs failed to prove efficacy. In this context, we investigated changes in MAPK signa...

Descripción completa

Detalles Bibliográficos
Autores principales: Knievel, Judith, Schulz, Wolfgang A., Greife, Annemarie, Hader, Christiane, Lübke, Tobias, Schmitz, Ingo, Albers, Peter, Niegisch, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264180/
https://www.ncbi.nlm.nih.gov/pubmed/25387078
http://dx.doi.org/10.3390/ijms151120500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264180/
https://www.ncbi.nlm.nih.gov/pubmed/25387078
http://dx.doi.org/10.3390/ijms151120500

Ejemplares similares